Squarepoint’s Viking Therapeutics VKTX Stock Holding History

Squarepoint’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$400K	Sell	12,300 -46,600	-79%	-$1.5M	﹤0.01%	3487
2025 Q4	$2.07M	Sell	58,900 -22,800	-28%	-$808K	﹤0.01%	2037
2025 Q3	$2.15M	Buy	+81,700	New	+$2.44M	﹤0.01%	2037
2025 Q2	–	Sell	-167,000	Closed	-$4.03M	–	5104
2025 Q1	$4.03M	Buy	167,000 +118,700	+246%	+$3.75M	﹤0.01%	1571
2024 Q4	$1.94M	Buy	48,300 +25,300	+110%	+$1.44M	﹤0.01%	2449
2024 Q3	$1.46M	Sell	23,000 -12,000	-34%	-$704K	﹤0.01%	2314
2024 Q2	$1.86M	Buy	+35,000	New	+$2.29M	﹤0.01%	2104

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Squarepoint's VKTX Position: Q3 2025 in Review

Squarepoint sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 55,355 shares — an estimated $1.65M sold.

Squarepoint first reported a position in VKTX in Q4 2018 and held it in 22 quarters. The position peaked at $10.8M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Squarepoint reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 55,355 Viking Therapeutics shares in Q3 2025, an estimated $1.65M.
Squarepoint first reported a position in Viking Therapeutics in Q4 2018 and held it in 22 quarters.
Squarepoint's Viking Therapeutics position peaked at $10.8M in Q4 2024.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.